Nanologica AB is a leading Swedish nanotechnology company that specializes in the manufacturing and sale of nanoporous silica particles for various life science applications. They have established themselves as world leaders in the development of silica particles for purification purposes in chromatography. With a primary focus on preparative chromatography, Nanologica's products are extensively used by pharmaceutical manufacturers for the purification of drugs during production, particularly peptide drugs like insulin and GLP-1 analogues.

What sets Nanologica apart is their proprietary production method, which allows them to precisely control the shape, size, porosity, and surface properties of silica particles. This enables the creation of top-notch products that offer more effective purification capabilities and longer-lasting performance. As a result, pharmaceutical manufacturers can streamline their production processes, reduce costs, and increase productivity.

Nanologica operates a pilot plant in Södertälje, Sweden, for small-scale silica production, customer support, and research and development. Large-scale production, on the other hand, takes place at a contract manufacturer in the UK. Nanologica's shares (NICA) are listed on the Nasdaq Stockholm Main Market since 2022.

Their vision is to enhance the accessibility and affordability of medicine through the use of porous silica, while their mission is to provide purification solutions that allow more patients worldwide to benefit from cost-effective treatments for diabetes and obesity. Nanologica aims to establish a rapidly growing, sustainable, and profitable business in the chromatography sector, with a specific focus on providing purification products for peptide-based drugs. They conduct sales directly and through partnerships in key markets such as India, China, the US, and Europe.

For more information, you can visit Nanologica's website or reach out to them via email or telephone